Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2023-12-01

FDA Approved: BAXDELA — Supplemental Application (Melinta Therapeutics, LLC)

View source ↗

Summary

The FDA approved a supplemental application for Baxdela (delafloxacin meglumine) submitted by Melinta Therapeutics, LLC. The update changes the drug’s labeling,…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • BAXDELA (delafloxacin meglumine)

Snippet

SUPPL AP for BAXDELA (DELAFLOXACIN MEGLUMINE)